> Back to EJC

Recent editions

  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.
  • November 2015
    Caroline Robert on new developments in immunotherapy.
  • October 2015
    Milena Sant on the latest results from the EUROCARE study.
  • September 2015
    The science behind the IARC code that could reduce cancer in Europe.
  • July/August 2015
    Thomas Helleday on an exciting new class of drug, MTH1 inhibitors.
  • June 2015
    Lesley Seymour and Jan Bogaerts on the future of RECIST.
  • May 2015
    Paul Workman on strategies for overcoming resistance to new drugs.
  • April 2015
    Highlights from the TAT Congress in Paris.
  • March 2015
    Christopher Wild on the exposome, a measure of environmental exposure.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – April 2013

Loading EJC News Focus video

What impact will an ageing population have in cancer?

The increasing burden of cancer in an ageing population is widely accepted, but more detailed discussion of the implications for patients, oncologists and healthcare systems is sometimes lacking. Elderly patients may of course need specific treatment approaches, but experts are calling for a more wide-ranging debate on measures that need to be put in place now to meet the needs of an ageing population. In this month's EJC News Focus, Richard Marais, David Cameron, Mary O'Brien, Roger Stupp, Manuela Schmidinger and Jan Willem Coebergh tell Helen Saul that it's time to re-look at screening and treatment guidelines, at survivorship issues, and the structures that will be needed to deal with co-morbidity.